M. Gillings

The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors

R. Bissonnette, F. Shojaei, R. Cesario, 2021, BMC cancer.

Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results

J. H. Lee, M. Kurosawa, J. Kuroda, 2022, Haematologica.

Oral histone deacetylase inhibitor tucidinostat (HBI‐8000) in patients with relapsed or refractory adult T‐cell leukemia/lymphoma: Phase IIb results

A. Utsunomiya, M. Kurosawa, K. Izutsu, 2022, Cancer science.

Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin’s lymphoma: phase I safety and efficacy

K. Tobinai, I. Choi, K. Ando, 2022, Japanese journal of clinical oncology.

Induction of apoptosis by HBI‐8000 in adult T‐cell leukemia/lymphoma is associated with activation of Bim and NLRP3

K. Yanagihara, D. Sasaki, N. Uno, 2016, Cancer science.

HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors

F. Kabbinavar, F. Shojaei, Bob Goodenow, 2022, Frontiers in Oncology.